The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
TRANSENTERIX INC | COM NEW | 89366M201 | 9,131 | 7,546,692 | SH | OTR | 1,2 | 0 | 7,546,692 | 0 | |
OCULAR THERAPEUTIX INC | COM | 67576A100 | 14,896 | 1,605,207 | SH | OTR | 1,2 | 0 | 1,605,207 | 0 | |
ENTELLUS MED INC | COM | 29363K105 | 40,801 | 2,956,456 | SH | OTR | 1,2 | 0 | 2,956,456 | 0 | |
CATABASIS PHARMACEUTICALS IN | COM | 14875P107 | 4,572 | 2,857,667 | SH | OTR | 0 | 2,857,667 | 0 | ||
LOMBARD MED INC | COM | G55598109 | 995 | 1,275,779 | SH | OTR | 1,2 | 0 | 1,275,779 | 0 | |
KALVISTA PHARMACEUTICALS INC | COM | 483497103 | 20,146 | 2,579,490 | SH | OTR | 1,2 | 0 | 2,579,490 | 0 |